In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.

MLA

Obermeier, M., et al. “In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans.” Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 38, no. 3, Mar. 2010, pp. 405–14. EBSCOhost, https://doi.org/10.1124/dmd.109.029165.

APA

Obermeier, M., Yao, M., Khanna, A., Koplowitz, B., Zhu, M., Li, W., Komoroski, B., Kasichayanula, S., Discenza, L., Washburn, W., Meng, W., Ellsworth, B. A., Whaley, J. M., & Humphreys, W. G. (2010). In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 38(3), 405–414. https://doi.org/10.1124/dmd.109.029165

Chicago

Obermeier, M, M Yao, A Khanna, B Koplowitz, M Zhu, W Li, B Komoroski, et al. 2010. “In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans.” Drug Metabolism and Disposition: The Biological Fate of Chemicals 38 (3): 405–14. doi:10.1124/dmd.109.029165.